PT3188599T - Tratamentos médicos baseados em anamorelina - Google Patents

Tratamentos médicos baseados em anamorelina

Info

Publication number
PT3188599T
PT3188599T PT158385484T PT15838548T PT3188599T PT 3188599 T PT3188599 T PT 3188599T PT 158385484 T PT158385484 T PT 158385484T PT 15838548 T PT15838548 T PT 15838548T PT 3188599 T PT3188599 T PT 3188599T
Authority
PT
Portugal
Prior art keywords
anamorelin
medical treatments
treatments based
medical
treatments
Prior art date
Application number
PT158385484T
Other languages
English (en)
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3188599(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of PT3188599T publication Critical patent/PT3188599T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
PT158385484T 2014-09-04 2015-08-28 Tratamentos médicos baseados em anamorelina PT3188599T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
PT3188599T true PT3188599T (pt) 2020-01-15

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158385484T PT3188599T (pt) 2014-09-04 2015-08-28 Tratamentos médicos baseados em anamorelina

Country Status (44)

Country Link
US (5) US9675600B2 (pt)
EP (2) EP3590338A3 (pt)
JP (3) JP6356907B2 (pt)
KR (3) KR102307275B1 (pt)
CN (5) CN113577073A (pt)
AP (1) AP2017009772A0 (pt)
AR (1) AR103118A1 (pt)
AU (1) AU2015312231B2 (pt)
BR (1) BR112017003552A2 (pt)
CA (1) CA2959158A1 (pt)
CL (1) CL2017000494A1 (pt)
CO (1) CO2017003263A2 (pt)
CR (1) CR20170121A (pt)
CY (1) CY1122746T1 (pt)
DK (1) DK3188599T3 (pt)
DO (1) DOP2017000055A (pt)
EA (1) EA035578B1 (pt)
EC (1) ECSP17019893A (pt)
ES (1) ES2761777T3 (pt)
GE (1) GEP20186939B (pt)
HR (1) HRP20192345T1 (pt)
HU (1) HUE046894T2 (pt)
IL (1) IL250692B (pt)
JO (1) JO3541B1 (pt)
LT (1) LT3188599T (pt)
MA (1) MA40607B1 (pt)
MD (1) MD4710C1 (pt)
ME (1) ME03597B (pt)
MX (1) MX361741B (pt)
MY (1) MY187167A (pt)
NI (1) NI201700024A (pt)
PE (1) PE20171109A1 (pt)
PH (1) PH12017500392A1 (pt)
PL (1) PL3188599T3 (pt)
PT (1) PT3188599T (pt)
RS (1) RS59751B1 (pt)
SG (1) SG11201701567UA (pt)
SI (1) SI3188599T1 (pt)
SV (1) SV2017005400A (pt)
TN (1) TN2017000040A1 (pt)
TW (1) TWI639429B (pt)
UA (1) UA120765C2 (pt)
UY (1) UY36286A (pt)
WO (1) WO2016036598A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701567UA (en) 2014-09-04 2017-03-30 Helsinn Healthcare Sa Medical treatments based on anamorelin
JP2022532547A (ja) 2019-05-10 2022-07-15 アイミューン セラピューティクス,インコーポレイテッド ピーナツアレルギー患者の生活の質を改善するための方法
EP4021419A1 (en) 2019-08-30 2022-07-06 Helsinn Healthcare SA Methods of manufacturing anamorelin tablets having improved stability
EP4049658A4 (en) * 2019-10-24 2023-11-22 Toray Industries, Inc. THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST CACHEXIA
WO2023042158A1 (en) * 2021-09-17 2023-03-23 Helsinn Healthcare Sa Methods of determining and providing clinically meaningful improvements on patient reported outcomes in anorexia / cachexia patients

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2005014032A2 (en) 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したc−反応性蛋白質の低減方法
JP5122950B2 (ja) * 2004-06-29 2013-01-16 ヘルシン セラピューティクス(ユー.エス.),インコーポレイティド (3r)−1−(2−メチルアラニル−d−トリプトフィル)−3−(フェニルメチル)−3−ピペリジンカルボン酸1,2,2−トリメチルヒドラジドの結晶形
EA200970764A1 (ru) * 2007-02-13 2010-04-30 ХЕЛСИНН ТЕРАПЬЮТИКС (Ю. Эс.), ИНК. Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
JP2015517452A (ja) 2012-05-25 2015-06-22 ラクオリア創薬株式会社 無酸症を治療するためのグレリン受容体アゴニスト
SG11201701567UA (en) 2014-09-04 2017-03-30 Helsinn Healthcare Sa Medical treatments based on anamorelin

Also Published As

Publication number Publication date
JP2018154655A (ja) 2018-10-04
US11723902B2 (en) 2023-08-15
HRP20192345T1 (hr) 2020-03-20
KR101881264B1 (ko) 2018-07-23
CY1122746T1 (el) 2021-03-12
KR20170047372A (ko) 2017-05-04
CL2017000494A1 (es) 2017-09-15
RS59751B1 (sr) 2020-02-28
CN113577074A (zh) 2021-11-02
CN113577073A (zh) 2021-11-02
JP6923486B2 (ja) 2021-08-18
CN109172575A (zh) 2019-01-11
US10894041B2 (en) 2021-01-19
JP2017526695A (ja) 2017-09-14
CR20170121A (es) 2017-07-17
KR102307275B1 (ko) 2021-09-30
US20160067236A1 (en) 2016-03-10
EP3188599A4 (en) 2017-10-11
TWI639429B (zh) 2018-11-01
MD20170025A2 (ro) 2017-07-31
AU2015312231A1 (en) 2017-03-23
PH12017500392B1 (en) 2017-07-17
EP3590338A3 (en) 2020-03-18
US20190175574A1 (en) 2019-06-13
MY187167A (en) 2021-09-07
CA2959158A1 (en) 2016-03-10
KR20180085047A (ko) 2018-07-25
DOP2017000055A (es) 2017-08-15
CN107205389A (zh) 2017-09-26
KR20210035923A (ko) 2021-04-01
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
BR112017003552A2 (pt) 2017-12-05
CO2017003263A2 (es) 2017-07-28
US20240024303A1 (en) 2024-01-25
IL250692B (en) 2019-05-30
MX2017002825A (es) 2017-09-28
KR102234319B1 (ko) 2021-04-01
IL250692A0 (en) 2017-04-30
MA40607B1 (fr) 2019-11-29
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
US20210093627A1 (en) 2021-04-01
JO3541B1 (ar) 2020-07-05
US10278964B2 (en) 2019-05-07
EP3590338A2 (en) 2020-01-08
SI3188599T1 (sl) 2020-02-28
AR103118A1 (es) 2017-04-19
NZ729673A (en) 2023-09-29
PE20171109A1 (es) 2017-08-07
AP2017009772A0 (en) 2017-02-28
SV2017005400A (es) 2017-04-20
ES2761777T3 (es) 2020-05-21
PL3188599T3 (pl) 2020-06-01
EP3188599B1 (en) 2019-10-02
NI201700024A (es) 2017-07-18
WO2016036598A1 (en) 2016-03-10
US9675600B2 (en) 2017-06-13
ME03597B (me) 2020-07-20
HUE046894T2 (hu) 2020-04-28
CN107375285A (zh) 2017-11-24
JP7044918B2 (ja) 2022-03-30
LT3188599T (lt) 2019-12-10
US20170296526A1 (en) 2017-10-19
TN2017000040A1 (en) 2018-07-04
JP6356907B2 (ja) 2018-07-11
JP2021080281A (ja) 2021-05-27
PH12017500392A1 (en) 2017-07-17
UY36286A (es) 2016-02-29
MD4710C1 (ro) 2021-04-30
MD4710B1 (ro) 2020-09-30
UA120765C2 (uk) 2020-02-10
EP3188599A1 (en) 2017-07-12
TW201613587A (en) 2016-04-16
AU2015312231B2 (en) 2017-10-19
MX361741B (es) 2018-12-14
ECSP17019893A (es) 2017-05-31
SG11201701567UA (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL247072A0 (en) Medical use
IL250387A0 (en) combined treatment
IL248856A0 (en) New treatment
EP3020328C0 (en) SKIN APPLICABLE MEDICAL DEVICE
GB201406989D0 (en) Novel treatments
IL250692B (en) Medical treatments based on anamorelin
PT3099317T (pt) Tripsina de bacalhau para utilização no tratamento de infeções microbianas num indivíduo com imunodeficiência
GB201412011D0 (en) Treatments
GB201403032D0 (en) Medical device
IL249240A0 (en) Combined treatment
GB201411027D0 (en) Treatment
GB201412285D0 (en) Therapeutic treatments
GB201412293D0 (en) Therapeutic treatments
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201419311D0 (en) Combination therapy
GB201417719D0 (en) New treatment
GB201408434D0 (en) Step treatment
GB201410147D0 (en) Medical device
GB201400235D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400240D0 (en) Treatment
GB201400239D0 (en) Treatment
GB201400238D0 (en) Treatment